西罗莫司治疗卡波西样血管内皮瘤中国专家共识（2026版）

doi:10.35541/cjd.20250541

Abstract

Abstract: 【Abstract】 Kaposiform hemangioendothelioma （KHE） is a rare locally aggressive vascular neoplasm that may be accompanied by coagulopathy, leading to disseminated intravascular coagulation and potentially life-threatening complications. The most recent consensus on the diagnosis and management of KHE recommends sirolimus as a first-line treatment for unresectable KHE, replacing traditional therapies such as glucocorticoids and vincristine, and has significantly improved patient survival and quality of life. To promote the scientific and standardized use of sirolimus in clinical practice, 33 senior experts from multiple disciplines with extensive experience in the diagnosis and treatment of KHE in China reviewed the latest evidence and integrated it with domestic clinical practice. Consensus recommendations were reached, and the “Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （2026 edition）” was developed.

Key words: Sirolimus, Kaposiform hemangioendothelioma, Therapy, Expert consensus

Expert Group on the “Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （ edition）”. Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （2026 edition）[J]. Chinese Journal of Dermatology, 2026, 59(8): 728-737.doi:10.35541/cjd.20250541

References ［93］

［1］	Wassef M, Blei F, Adams D, et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies［J］. Pediatrics, 2015,136（1）:203⁃214. DOI: 10.1542/peds.2014⁃3673.
［2］	Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach⁃Merritt syndrome and lymphangiomatosis［J］. Am J Surg Pathol, 1993,17（4）:321⁃328. DOI: 10.1097/00000478⁃199304000⁃00001.
［3］	Zhou J, Yang K, Dai S, et al. Clinical features and management of Kaposiform hemangioendothelioma and tufted angioma: similarities and differences［J］. J Am Acad Dermatol, 2022,87（1）:172⁃174. DOI: 10.1016/j.jaad.2021.07.012.
［4］	Nieto⁃Benito LM, Huerta⁃Aragonés J, Parra⁃Blanco V, et al. Kaposiform hemangioendothelioma and tufted angioma: two entities of the same clinicopathological spectrum［J］. An Bras Dermatol, 2023,98（3）:391⁃394. DOI: 10.1016/j.abd.2021.07.010.
［5］	代诗懿, 杨开颖, 邱桐, 等. 卡波西样血管内皮瘤117例临床分析［J］. 中国皮肤性病学杂志, 2020,34（5）:542⁃549. DOI: 10.13735/j.cjdv.1001⁃7089.201908138.
［6］	兰钰茹, 周江元, 邱桐, 等. 卡波西样血管内皮瘤来源内皮细胞的分离、纯化、鉴定、培养与表型分析［J］. 中华皮肤科杂志, 2025,58（5）:453⁃459. DOI: 10.35541/cjd.20240400.
［7］	Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach⁃Merritt phenomenon in 107 referrals［J］. J Pediatr, 2013,162（1）:142⁃147. DOI: 10.1016/j.jpeds.2012.06.044.
［8］	Ji Y, Chen S, Yang K, et al. Kaposiform hemangioendothelioma: current knowledge and future perspectives［J］. Orphanet J Rare Dis, 2020,15（1）:39. DOI: 10.1186/s13023⁃020⁃1320⁃1.
［9］	Lim YH, Bacchiocchi A, Qiu J, et al. GNA14 somatic mutation causes congenital and sporadic vascular tumors by MAPK activation［J］. Am J Hum Genet, 2016,99（2）:443⁃450. DOI: 10.1016/j.ajhg.2016.06.010.
［10］	Hall GW. Kasabach⁃Merritt syndrome: pathogenesis and management［J］. Br J Haematol, 2001,112（4）:851⁃862. DOI: 10.1046/j.1365⁃2141.2001.02453.x.
［11］	代诗懿, 彭素华, 陈思源, 等. 卡波西样血管内皮瘤的研究进展［J］. 临床小儿外科杂志, 2020,19（6）:544⁃547,553.
［12］	陈辉, 林晓曦, 林梅绥, 等. 伴Kasabach⁃Merritt现象卡波西形血管内皮瘤和丛状血管瘤的临床及病理特征［J］. 中华皮肤科杂志, 2009,42（10）:674⁃676. DOI: 10.3760/cma.j.issn.0412⁃4030.2009.10.006.
［13］	O'Rafferty C, O'Regan GM, Irvine AD, et al. Recent advances in the pathobiology and management of Kasabach⁃Merritt phenomenon［J］. Br J Haematol, 2015,171（1）:38⁃51. DOI: 10.1111/bjh.13557.
［14］	Borst AJ, Eng W, Griffin M, et al. Treatment practices and response in Kaposiform hemangioendothelioma: a multicenter cohort study［J］. Pediatr Blood Cancer, 2024,71（3）:e30779. DOI: 10.1002/pbc.30779.
［15］	Liu X, Li J, Qu X, et al. Clinical outcomes for systemic corticosteroids versus vincristine in treating Kaposiform hemangioendothelioma and tufted angioma［J］. Medicine （Baltimore）, 2016,95（20）:e3431. DOI: 10.1097/MD.00000000 00003431.
［16］	Liu XH, Li JY, Qu XH, et al. Treatment of Kaposiform hemangioendothelioma and tufted angioma［J］. Int J Cancer, 2016,139（7）:1658⁃1666. DOI: 10.1002/ijc.30216.
［17］	Yao W, Li K, Wang Z, et al. Comparison of efficacy and safety of corticosteroid and vincristine in treating Kaposiform hemangioendothelioma and tufted angioma: a multicenter prospective randomized controlled clinical trial［J］. J Dermatol, 2021,48（5）:576⁃584. DOI: 10.1111/1346⁃8138.15767.
［18］	Li G, Hu Y, Li D, et al. Vincristine⁃induced peripheral neuropathy: a mini⁃review［J］. Neurotoxicology, 2020,81:161⁃171. DOI: 10.1016/j.neuro.2020.10.004.
［19］	Drolet BA, Trenor cc, brandão lr, et al. Consensus⁃derived practice standards plan for complicated Kaposiform hemangioendothelioma［J］. J Pediatr, 2013,163（1）:285⁃291. DOI: 10.1016/j.jpeds.2013.03.080.
［20］	Blatt J, Stavas J, Moats⁃Staats B, et al. Treatment of childhood Kaposiform hemangioendothelioma with sirolimus［J］. Pediatr Blood Cancer, 2010,55（7）:1396⁃1398. DOI: 10.1002/pbc.22766.
［21］	杨家健. 西罗莫司治疗婴幼儿卡梅现象的研究进展［J］. 儿科药学杂志, 2019,25（6）:55⁃58. DOI: 10.13407/j.cnki.jpp.1672⁃108X.2019.06.018.
［22］	Wang J, Han Q, Yan H, et al. Overexpression Prox1 in HemECs resembles Kaposiform hemangioendothelioma and cytotoxicity of sirolimus in vitro［J］. J Pediatr Surg, 2021,56（7）:1203⁃1210. DOI: 10.1016/j.jpedsurg.2021.03.023.
［23］	Qiu T, Xiang S, Zhou J, et al. Sirolimus for Kaposiform hemangioendothelioma: potential mechanisms of action and resistance［J］. Int J Cancer, 2025,156（4）:689⁃699. DOI: 10. 1002/ijc.35207.
［24］	Peng S, Yang K, Xu Z, et al. Vincristine and sirolimus in the treatment of Kaposiform haemangioendothelioma［J］. J Paediatr Child Health, 2019,55（9）:1119⁃1124. DOI: 10.1111/jpc.14370.
［25］	Wang H, Duan Y, Gao Y, et al. Sirolimus for vincristine⁃resistant kasabach⁃merritt phenomenon: report of eight patients［J］. Pediatr Dermatol, 2017,34（3）:261⁃265. DOI: 10.1111/pde. 13077.
［26］	Ji Y, Chen S, Xiang B, et al. Sirolimus for the treatment of progressive Kaposiform hemangioendothelioma: a multicenter retrospective study［J］. Int J Cancer, 2017,141（4）:848⁃855. DOI: 10.1002/ijc.30775.
［27］	Zhou J, Li Y, Qiu T, et al. Long⁃term outcomes of sirolimus treatment for Kaposiform hemangioendothelioma: continuing successes and ongoing challenges［J］. Int J Cancer. 2023;153（3）:600⁃608. DOI: 10.1002/ijc.34509.
［28］	何瑞, 张斌, 李丽, 等. 外用西罗莫司治疗儿童浅表脉管畸形19例的临床疗效及安全性分析［J］. 中华皮肤科杂志, 2022,55（2）:129⁃134. DOI: 10.35541/cjd.20210629.
［29］	李云玲, 郑惠文, 李寅, 等. 西罗莫司联合普萘洛尔治疗婴儿蓝色橡皮疱痣综合征一例［J］. 中华皮肤科杂志, 2020,2020（7）:564⁃565. DOI: 10.35541/cjd.20190309.
［30］	王跃生, 张敬, 李小芹, 等. 西罗莫司治疗儿童蓝色橡皮疱痣综合征1例［J］. 中华皮肤科杂志, 2022,55（9）:810⁃811. DOI: 10.35541/cjd.20200219.
［31］	卡波西样血管内皮瘤诊疗专家共识小组. 卡波西样血管内皮瘤诊疗中国专家共识（2023）［J］. 中华小儿外科杂志, 2024,45（1）:1⁃9. DOI: 10.3760/cma.j.cn421158⁃20231019⁃00419.
［32］	Zhou J, Qiu T, Zhang Z, et al. Consensus statement for the diagnosis, treatment, and prognosis of Kaposiform hemangioendothelioma［J］. Int J Cancer, 2025,156（10）:1986⁃1994. DOI: 10.1002/ijc.35344.
［33］	Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations［J］. BMJ, 2008,336（7650）:924⁃926. DOI: 10.1136/bmj.39489.470347.AD.
［34］	Popova NV, Jücker M. The role of mTOR signaling as a therapeutic target in cancer［J］. Int J Mol Sci, 2021,22（4）:1743. DOI: 10.3390/ijms22041743.
［35］	Weyrich AS, Denis MM, Schwertz H, et al. mTOR⁃dependent synthesis of Bcl⁃3 controls the retraction of fibrin clots by activated human platelets［J］. Blood, 2007,109（5）:1975⁃1983. DOI: 10.1182/blood⁃2006⁃08⁃042192.
［36］	Wang L, Liu G, Wu N, et al. mTOR regulates GPVI⁃mediated platelet activation［J］. J Transl Med, 2021,19（1）:201. DOI: 10. 1186/s12967⁃021⁃02756⁃y.
［37］	Aslan JE, Tormoen GW, Loren CP, et al. S6K1 and mTOR regulate Rac1⁃driven platelet activation and aggregation［J］. Blood, 2011,118（11）:3129⁃3136. DOI: 10.1182/blood⁃2011⁃02⁃331579.
［38］	Cras TDL, Mobberley⁃Schuman PS, Broering M, et al. Angiopoietins as serum biomarkers for lymphatic anomalies［J］. Angiogenesis, 2017,20（1）:163⁃173. DOI: 10.1007/s10456⁃016⁃9537⁃2.
［39］	Conciatori F, Bazzichetto C, Falcone I, et al. Role of mTOR signaling in tumor microenvironment: an overview［J］. Int J Mol Sci, 2018,19（8）. DOI: 10.3390/ijms19082453.
［40］	Ji Y, Chen S, Li K, et al. Signaling pathways in the development of infantile hemangioma［J］. J Hematol Oncol, 2014,7:13. DOI: 10.1186/1756⁃8722⁃7⁃13.
［41］	Wang Z, Han Q, Wang J, et al. Rapamycin induces autophagy and apoptosis in Kaposiform hemangioendothelioma primary cells in vitro［J］. J Pediatr Surg, 2022,57（7）:1274⁃1280. DOI: 10.1016/j.jpedsurg.2022.02.032.
［42］	Li Y, Zhu X, Li L, et al. Construction and applications of the EOMA spheroid model of Kaposiform hemangioendothelioma［J］. J Biol Eng, 2024,18（1）:21. DOI: 10.1186/s13036⁃024⁃00417⁃4.
［43］	Zhang Y, Zhang C, Li L, et al. Lymphangiogenesis in renal fibrosis arises from macrophages via VEGF⁃C/VEGFR3⁃dependent autophagy and polarization［J］. Cell Death Dis, 2021,12（1）:109. DOI: 10.1038/s41419⁃020⁃03385⁃x.
［44］	Pei G, Yao Y, Yang Q, et al. Lymphangiogenesis in kidney and lymph node mediates renal inflammation and fibrosis［J］. Sci Adv, 2019,5（6）:eaaw5075. DOI: 10.1126/sciadv.aaw5075.
［45］	Ji Y, Yang K, Chen S, et al. Musculoskeletal complication in Kaposiform hemangioendothelioma without Kasabach⁃Merritt phenomenon: clinical characteristics and management［J］. Cancer Manag Res, 2018,10:3325⁃3331. DOI: 10.2147/CMAR.S171223.
［46］	石浩强, 陈冰, 许倍铭. 西罗莫司药动学的影响因素及治疗药物监测［J］. 中国医药工业杂志, 2010,41（7）:543⁃547.
［47］	Wang D, Chen X, Li Z. Population pharmacokinetics of sirolimus in pediatric patients with Kaposiform hemangioendothelioma: a retrospective study［J］. Oncol Lett, 2019,18（3）:2412⁃2419. DOI: 10.3892/ol.2019.10562.
［48］	Johnson TN, Thomson M. Intestinal metabolism and transport of drugs in children: the effects of age and disease［J］. J Pediatr Gastroenterol Nutr, 2008,47（1）:3⁃10. DOI: 10.1097/MPG.0b0 13e31816a8cca.
［49］	Mizuno T, Fukuda T, Emoto C, et al. Developmental pharmacokinetics of sirolimus: implications for precision dosing in neonates and infants with complicated vascular anomalies［J］. Pediatr Blood Cancer, 2017,64（8）:26470. DOI: 10.1002/pbc.26470.
［50］	Fakhoury M, Litalien C, Medard Y, et al. Localization and mRNA expression of CYP3A and P⁃glycoprotein in human duodenum as a function of age［J］. Drug Metab Dispos, 2005,33（11）:1603⁃1607. DOI: 10.1124/dmd.105.005611.
［51］	Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity［J］. Clin Transplant, 2000,14（2）:97⁃109. DOI: 10.1034/j.1399⁃0012.2000.140201.x.
［52］	Zhang J, Dai Y, Liu Z, et al. Effect of CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of sirolimus in healthy Chinese volunteers［J］. Ther Drug Monit, 2017,39（4）:406⁃411. DOI: 10.1097/FTD.0000000000000415.
［53］	McCune JS, Bemer MJ, Long⁃Boyle J. Pharmacokinetics, pharmacodynamics, and pharmacogenomics of immunosuppressants in allogeneic hematopoietic cell transplantation: partⅡ［J］. Clin Pharmacokinet, 2016,55（5）:551⁃593. DOI: 10.1007/s40262⁃015⁃0340⁃9.
［54］	Jimeno A, Rudek MA, Kulesza P, et al. Pharmacodynamic⁃guided modified continuous reassessment method⁃based, dose⁃finding study of rapamycin in adult patients with solid tumors［J］. J Clin Oncol, 2008,26（25）:4172⁃4179. DOI: 10.1200/JCO.2008.16.2347.
［55］	Jiao Z, Shi X, Li Z, et al. Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients［J］. Br J Clin Pharmacol, 2009,68（1）:47⁃60. DOI: 10.1111/j.1365⁃2125.2009.03392.x.
［56］	Kai L, Wang Z, Yao W, et al. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma［J］. J Cancer Res Clin Oncol, 2014,140（3）:471⁃476. DOI: 10.1007/s00432⁃013⁃1549⁃3.
［57］	Schmid I, Klenk AK, Sparber⁃Sauer M, et al. Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options［J］. World J Pediatr, 2018,14（4）:322⁃329. DOI: 10.1007/s12519⁃018⁃0171⁃5.
［58］	Ji Y, Chen S, Zhou J, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for Kaposiform hemangioendothelioma: a randomized clinical trial［J］. Blood, 2022,139（11）:1619⁃1630. DOI: 10.1182/blood.2021014027.
［59］	Zhou J, Lan Y, Qiu T, et al. Efficacy and safety of high⁃ vs low⁃dose sirolimus in patients with Kaposiform hemangioendothelioma: a randomized clinical trial［J］. J Am Acad Dermatol, 2025,93（1）:124⁃131. DOI: 10.1016/j.jaad.2025.03.023.
［60］	Brill R, Uller W, Huf V, et al. Additive value of transarterial embolization to systemic sirolimus treatment in Kaposiform hemangioendothelioma［J］. Int J Cancer, 2021,148（9）:2345⁃2351. DOI: 10.1002/ijc.33406.
［61］	Shan Y, Tian R, Gao H, et al. Sirolimus for the treatment of Kaposiform hemangioendothelioma: in a trough level⁃dependent way［J］. J Dermatol, 2021,48（8）:1201⁃1209. DOI: 10.1111/1346⁃8138.15905.
［62］	Liu B, Zhang X, Zhao Y, et al. Model⁃informed individualized dosage regimen of sirolimus in pediatric patients with intractable lymphatic malformations［J］. Eur J Pharm Sci, 2024,200:106837. DOI: 10.1016/j.ejps.2024.106837.
［63］	Zimmerman JJ, Patat A, Parks V, et al. Pharmacokinetics of sirolimus （rapamycin） in subjects with severe hepatic impairment［J］. J Clin Pharmacol, 2008,48（3）:285⁃292. DOI: 10.1177/0091270007312902.
［64］	Ji Y, Yang K, Peng S, et al. Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach⁃Merritt phenomenon［J］. Br J Dermatol, 2018,179（2）:457⁃463. DOI: 10.1111/bjd.16601.
［65］	Ettenger RB, Grimm EM. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients［J］. Am J Kidney Dis, 2001,38（4 Suppl 2）:22⁃28. DOI: 10.1053/ajkd.2001.27838.
［66］	Wang Z, Yao W, Sun H, et al. Sirolimus therapy for Kaposiform hemangioendothelioma with long⁃term follow⁃up［J］. J Dermatol, 2019,46（11）:956⁃961. DOI: 10.1111/1346⁃8138.15076.
［67］	Ji Y, Chen S, Yang K, et al. A prospective multicenter study of sirolimus for complicated vascular anomalies［J］. J Vasc Surg, 2021,74（5）:1673⁃1681. DOI: 10.1016/j.jvs.2021.04.071.
［68］	周江元, 杨开颖, 彭素华, 等. 西罗莫司联合泼尼松治疗卡波西样血管内皮瘤伴Kasabach⁃Merritt现象初探［J］. 中华皮肤科杂志, 2020,（7）:514⁃518. DOI: 10.35541/cjd.20191172.
［69］	Yin C, Qi W, Wang S, et al. Efficacy of transcatheter arterial chemoembolization combined with sirolimus for treating Kasabach⁃Merritt phenomenon in infants, a retrospective study［J］. Ann Med, 2023,55（1）:2196090. DOI: 10.1080/07853890. 2023.2196090.
［70］	Thomas KV, Le T, Messele F, et al. Adding to your tool box: laser therapy for vascular anomalies［J］. Pediatr Dermatol, 2025,42（4）:716⁃727. DOI: 10.1111/pde.15991.
［71］	Zhang X, Yang K, Chen S, et al. Tacrolimus ointment for the treatment of superficial Kaposiform hemangioendothelioma and tufted angioma［J］. J Dermatol, 2019,46（10）:898⁃901. DOI: 10. 1111/1346⁃8138.15031.
［72］	Xiu B, Xu Z, Xu Z, et al. Additive therapeutic effects of topical sirolimus following oral propranolol therapy for Kaposiform hemangioendothelioma［J］. Clin Cosmet Investig Dermatol, 2025,18:1261⁃1267. DOI: 10.2147/CCID.S520410.
［73］	Wang Z, Li K, Yao W, et al. Steroid⁃resistant Kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long⁃term follow⁃up［J］. Pediatr Blood Cancer, 2015,62（4）:577⁃580. DOI: 10.1002/pbc.25296.
［74］	Qiu T, Li Y, Gong X, et al. Oral antibiotic prophylaxis for infection in patients with vascular anomalies receiving sirolimus treatment: a multicenter retrospective study［J］. Orphanet J Rare Dis, 2023,18（1）:121. DOI: 10.1186/s13023⁃023⁃02740⁃3.
［75］	Zimmerman JJ, Ferron GM, Lim HK, et al. The effect of a high⁃fat meal on the oral bioavailability of the immunosuppressant sirolimus （rapamycin）［J］. J Clin Pharmacol, 1999,39（11）:1155⁃1161.
［76］	Deblon N, Bourgoin L, Veyrat⁃Durebex C, et al. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats［J］. Br J Pharmacol, 2012,165（7）:2325⁃2340. DOI: 10.1111/j.1476⁃5381.2011.01716.x.
［77］	Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes［J］. Int J Pharm, 2004,277（1⁃2）:3⁃9. DOI: 10.1016/j.ijpharm.2002. 12.002.
［78］	Paine MF, Leung LY, Lim HK, et al. Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion［J］. J Pharmacol Exp Ther, 2002,301（1）:174⁃186. DOI: 10.1124/jpet.301.1.174.
［79］	Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression［J］. J Clin Invest, 1997,99（10）:2545⁃2553. DOI: 10.1172/JCI119439.
［80］	Cohen EEW, Wu K, Hartford C, et al. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients［J］. Clin Cancer Res, 2012,18（17）:4785⁃4793. DOI: 10.1158/1078⁃0432.CCR⁃12⁃0110.
［81］	Worthy T, Jones A, Yang BE, et al. Effects of sirolimus on anti⁃SARS⁃CoV⁃2 vaccination in patients with lymphangioleiomyomatosis［J］. Chest, 2024,165（2）:303⁃306. DOI: 10.1016/j.chest.2023. 09.014.
［82］	Willcocks LC, Chaudhry AN, Smith JC, et al. The effect of sirolimus therapy on vaccine responses in transplant recipients［J］. Am J Transplant, 2007,7（8）:2006⁃2011. DOI: 10.1111/j.1600⁃6143.2007.01869.x.
［83］	Yuan J, Yuan Z, Ding Y, et al. Safety and immunogenicity of vaccines in children with Kaposiform hemangioendothelioma receiving sirolimus: a prospective study［J］. Vaccines （Basel）, 2025,13（9）:903. DOI: 10.3390/vaccines13090903.
［84］	Maruani A, Tavernier E, Boccara O, et al. Sirolimus （rapamycin） for slow⁃flow malformations in children: the observational⁃phase randomized clinical PERFORMUS trial［J］. JAMA Dermatol, 2021,157（11）:1289⁃1298. DOI: 10.1001/jamadermatol.2021.3459.
［85］	The Breast Cancer Expert Committee of the National Quality Control Center for Cancer, The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center, The Society of Clinical Research on Oncology Medications of the China Anti⁃Cancer Association and The Society of Onco⁃Pathology of the China Anti⁃Cancer Association （2025）. Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of breast cancer （2025 edition）［J］. Cancer Innov. 2025,4（3）:e70008. DOI: 10.1002/cai2.70008.
［86］	Gulde A, Hasanov E, Krug K, et al. Everolimus⁃induced pneumonitis: a diagnostic challenge［J］. Breast J, 2020,26（2）:287⁃288. DOI: 10.1111/tbj.13554.
［87］	Peterson DE, Boers⁃Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow⁃up［J］. Ann Oncol, 2015,26 Suppl 5:v139⁃151. DOI: 10.1093/annonc/mdv202.
［88］	Chambers MS, Rugo HS, Litton JK, et al. Stomatitis associated with mammalian target of rapamycin inhibition: a review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer［J］. J Am Dent Assoc, 2018,149（4）:291⁃298. DOI: 10.1016/j.adaj.2017.10.024.
［89］	Hong JC, Kahan BD. Sirolimus⁃induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management［J］. Transplantation, 2000,69（10）:2085⁃2090. DOI: 10.1097/00007890⁃200005270⁃00019.
［90］	Sun Q, Wu J, Chen X, et al. Efficacy and safety of sirolimus in the treatment of gastrointestinal angiodysplasias［J］. World J Gastroenterol, 2025,31（25）:105677. DOI: 10.3748/wjg.v31.i25. 105677.
［91］	Chen J, He W, Wang Y, et al. Long⁃term administration of sirolimus does not affect the physical development of children with tuberous sclerosis complex［J］. Childs Nerv Syst, 2022,38（5）:947⁃952. DOI: 10.1007/s00381⁃022⁃05446⁃2.
［92］	Pham PT, Pham PT, Danovitch GM, et al. Sirolimus⁃associated pulmonary toxicity［J］. Transplantation, 2004,77（8）:1215⁃1220. DOI: 10.1097/01.tp.0000118413.92211.b6.
［93］	Morath C, Schwenger V, Ksoll⁃Rudek D, et al. Four cases of sirolimus⁃associated interstitial pneumonitis: identification of risk factors［J］. Transplant Proc, 2007,39（1）:99⁃102. DOI: 10. 1016/j.transproceed.2006.10.219.

[1]	LIN Neng-xing, ZHANG Li-xia, HUANG Chang-zheng, CHEN Hong-xiang, TU Ya-ting. The Mutation of IR Gene in the mtr System and Multiple Antibiotic Resistance of Neisseria gonorrhoeae[J]. Chinese Journal of Dermatology, 2005, 38(12): 719 -721 .
[2]	. [J]. Chinese Journal of Dermatology, 2005, 38(12): 767 .
[3]	. [J]. Chinese Journal of Dermatology, 2005, 38(12): 768 -769 .
[4]	. [J]. Chinese Journal of Dermatology, 2005, 38(12): 774 .
[5]	李靖华, 周晓鸿. [J]. Chinese Journal of Dermatology, 2005, 38(12): 775 .
[6]	. [J]. Chinese Journal of Dermatology, 2005, 38(12): 777 -778 .
[7]	ZHANG Li, WANG Zhen-ying, WEI Xin-jing, LIU Chen-fan. Detection of Gene Mutations in a Family of Congenital Atrichia with Papular Lesions[J]. Chinese Journal of Dermatology, 2005, 38(11): 668 -670 .
[8]	CHEN Hong-xiang, LIN Neng-xing, HUANG Chang-zheng, LI Jia-wen, LIU Hou-jun, TU Ya-ting. Construction of a Prokaryotic Expression Plasmid Encoding the mtrC Gene of N.gonorrhoeae and Its Expression in E.coli[J]. Chinese Journal of Dermatology, 2005, 38(11): 674 -676 .
[9]	. [J]. Chinese Journal of Dermatology, 2005, 38(11): 697 -698 .
[10]	孙志平, 邱实, 谭升顺. [J]. Chinese Journal of Dermatology, 2005, 38(11): 676 .

[1]	Writing Committee Expert Group on “Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （ edition）”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(8): 717-727.
[2]	Li Yanhong, Jiang Kun, Wu Zhuoxuan, Zhang Jianlan, Fang Meizhen, Liu Shuting, Wang Linlin, Hu Lei, Zhou Xiaoyong, Chen Liuqing, Chen Jinbo. Analysis of 18 cases of cutaneous adverse reactions associated with programmed death-1 inhibitors [J]. Chinese Journal of Dermatology, 2026, 59(8): 783-787.
[3]	Wei Jin¹, Yan Huiwen¹, Zhang Jianzhong², Lun Wenhui¹. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis complicated by HIV infection: a clinical observation of 10 cases [J]. Chinese Journal of Dermatology, 2026, 59(7): 671-674.
[4]	Wang Linlin, Cao Lijuan, Chen Liuqing, Li Dongsheng, Hu Yanyan. Efficacy and safety of hemoporfin-mediated photodynamic therapy for port-wine stains on the extremities: a retrospective analysis [J]. Chinese Journal of Dermatology, 2026, 59(7): 637-644.
[5]	Zhang Guolong, Zhao Zijun. Aminolevulinic acid-based photodynamic therapy for cutaneous squamous cell carcinoma: current status, challenges, and perspectives [J]. Chinese Journal of Dermatology, 2026, 59(7): 626-631.
[6]	Hu Yu, Lu Yan, Chen Kun, Gu Heng. Standardization, precision, and full-cycle management: interpretation of Specifications for the Management of Vitiligo Patients Undergoing Home Phototherapy [J]. Chinese Journal of Dermatology, 2026, 59(7): 632-636.
[7]	Dermatology Professional Committee of Chinese Research Hospital Society, China Dermatologist Association. Guideline for the clinical application of narrowband ultraviolet B phototherapy in dermatology （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(7): 595-610.
[8]	Photodynamic Therapy Research Cooperative Group, Chinese Society of Dermatology, Chinese Association of Rehabilitation Dermatology & Photodynamic Therapy, Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Guideline for the clinical application of aminolevulinic acid-based photodynamic therapy in the treatment of condyloma acuminatum （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(7): 611-618.
[9]	Pediatric Dermatology Group, Chinese Society of Dermatology, Dermatology Group, Chinese Pediatric Society, Chinese Medical Association, Pediatric Group, Chinese Association of Rehabilitation Dermatology, Atopic Dermatitis Group, Chinese Association of Rehabilitation Dermatology, Pediatric Dermatology Group, China Dermatologist Association, Dermatology Group, the Society of Pediatrics, Chinese Medical Doctor Association. Chinese consensus on the prevention, treatment, and management of atopic dermatitis in children（2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(6): 487-504.
[10]	Sun Songpeng, Long Junhong, Cao Bo, Xu Yue, Zhang Xiang′an, Cao Hui, Xie Jun, Gui Ping, Sun Xiaojun, Zhang Bo, Xu Zhijie, Li Jin′an, Wang Zhigang, Wu Wei, Yang Huiju, Wei Ping, Liu Congcong, Shen Qingbo, Yu Fan, Chu Hongchuan, Zhou Yangyang, Liu Jiaxin, Liu Yan, Huo Xingxiao, Chen Hang, Jing Tao, Gao Jing, Wang Yanxun, Wang Rui, Li Zhenyu, Zhang Shuxin. Efficacy and safety of Fuzhiqing ointment versus triamcinolone acetonide and econazole nitrate cream in the treatment of chronic perianal eczema: a multicenter, randomized, double-blind, controlled, equivalence trial [J]. Chinese Journal of Dermatology, 2026, 59(6): 564-570.
[11]	Xu Zhuohong, Zhou Huan, Hu Yu, Gu Heng. Balneotherapy in skin diseases [J]. Chinese Journal of Dermatology, 2026, 59(5): 482-485.
[12]	Chinese Association of Rehabilitation Dermatology, Combination of Traditional and Western Medicine Dermatology. Expert consensus on the diagnosis, treatment and rehabilitation of psoriasis in the elderly （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(5): 407-418.
[13]	Hair Disease Rehabilitation Group, Chinese Association of Rehabilitation Dermatology, Hair Medicine Branch, Beijing Association of Holistic Integrative Medicine, Hair Research Group, Chinese Society of Dermatology, National Clinical Research Center for Dermatologic and Immunologic Diseases. Chinese expert consensus on hair biopsy and pathology （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(5): 419-426.
[14]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, Dermatology Branch of China Alliance for Rare Diseases. Expert consensus on fecal microbiota transplantation in the treatment of psoriasis （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(5): 427-435.
[15]	Zhang Xiaoxu, Luo Suju. Efficacy and safety of upadacitinib in the treatment of six cases of palmoplantar pustulosis [J]. Chinese Journal of Dermatology, 2026, 59(5): 459-463.

Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （2026 edition）

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［93］

Related Articles 15

Metrics

Comments

Recommended 10